Strategy remains centered on an early-stage Rx-to-OTC switch technology platform spanning SaaS and a potential FDA-governed SaMD consumer interface.
Half-year results and expenses
Petros Pharmaceuticals posted a GAAP net loss of $1.94 million for the six months ended June 30, 2026, versus GAAP net income of $3.17 million a year earlier.
Selling, general and administrative expense fell 38.2% to $2.02 million, on lower professional service fees tied to the absence of ABC-related costs.
Interest income slipped to $72,120 from $136,639 as cash balances available for investing declined.
Cash position and going-concern warning
Cash and cash equivalents were about $3.5 million at June 30, 2026; management flagged substantial doubt about continuing as a going concern.
PTPI•
